EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Bridge‐to‐transplant temporary mechanical circulatory support and risk of allosensitization

Konstantinos Sideris iD, Eszter Lázár-Molnár iD, Christos P Kyriakopoulos iD, Iosif Taleb, Denise Hurst, Sharon Ugolini, Craig H Selzman, Lina Brinker, Stavros G Drakos, Joseph E Tonna, Laura Geer, Matthew L Goodwin and 5 more

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15330 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Konstantinos Sideris and 16 co-authors. Institution: Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA. Major MEDLINE topics: Heart-Assist Devices, Heart Transplantation, Isoantibodies. Cited 1 times so far (Crossref); 11 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Introduction

Since the 2018 change in the US adult heart allocation policy, more patients are bridged‐to‐transplant on temporary mechanical circulatory support (tMCS). Previous studies indicate that durable left ventricular assist devices (LVAD) may lead to allosensitization. The goal of this study was to assess whether tMCS implantation is associated with changes in sensitization.

Methods

We included patients evaluated for heart transplants between 2015 and 2022 who had alloantibody measured before and after MCS implantation. Allosensitization was defined as development of new alloantibodies after tMCS implant.

Results

A total of 41 patients received tMCS before transplant. Nine (22.0%) patients developed alloantibodies following tMCS implantation: 3 (12.0%) in the intra‐aortic balloon pump group ( n = 25), 2 (28.6%) in the microaxial percutaneous LVAD group ( n = 7), and 4 (44.4%) in the veno‐arterial extra‐corporeal membrane oxygenation group ( n = 9)— p = .039. Sensitized patients were younger (44.7 ± 11.6 years vs. 54.3 ± 12.5 years, p = .044), were more likely to be sensitized at baseline ‐ 4 of 9 (44.4%) compared to 1 out of 32 (3.1%) ( p = .001) and received more transfusions with red blood cells (6 (66.7%) vs. 8 (25%), p = .02) and platelets (6 (66.7%) vs. 5 (15.6%), p = .002). There was no significant difference in tMCS median duration of support (4 [3,15] days vs. 8.5 [5,14.5] days, p = .57). Importantly, out of the 11 patients who received a durable LVAD after tMCS, 5 (45.5%) became sensitized, compared to 4 out of 30 patients (13.3%) who only had tMCS— p = .028.

Conclusions

Our findings suggest that patients bridged‐to‐transplant with tMCS, without significant blood product transfusions and a subsequent durable LVAD implant, have a low risk of allosensitization. Further studies are needed to confirm our findings and determine whether risk of sensitization varies by type of tMCS and duration of support.

Subjects

MeSH terms (MEDLINE)

Heart-Assist DevicesHeart TransplantationIsoantibodiesHumansMaleFemaleMiddle AgedFollow-Up StudiesAdultRisk FactorsPrognosisRetrospective StudiesHeart FailureGraft Rejection

Author keywords

allosensitizationheart transplanttemporary mechanical circulatory support

Substances

Isoantibodies

Authors and institutions

  • Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Division of Cardiothoracic Surgery, University of Utah School of Medicine, Salt Lake City, Utah, USA.

ORCID profiles: Konstantinos Sideris, Eszter Lázár-Molnár, Christos P Kyriakopoulos, Josef Stehlik

Funding

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Cite

APA

Sideris, K., Lázár-Molnár, E., Kyriakopoulos, C. P., Taleb, I., Hurst, D., Ugolini, S., Selzman, C. H., Brinker, L., Drakos, S. G., Tonna, J. E., Geer, L., Goodwin, M. L., Wever-Pinzon, O., Hanff, T. C., Fang, J. C., Carter, S., & Stehlik, J. (2024). Bridge‐to‐transplant temporary mechanical circulatory support and risk of allosensitization. Clinical Transplantation. https://doi.org/10.1111/ctr.15330

Vancouver

Sideris K, Lázár-Molnár E, Kyriakopoulos CP, Taleb I, Hurst D, Ugolini S, et al. Bridge‐to‐transplant temporary mechanical circulatory support and risk of allosensitization. Clinical Transplantation. 2024. doi:10.1111/ctr.15330

BibTeX
@article{Sideris2024,
  author = {Sideris, Konstantinos and Lázár-Molnár, Eszter and Kyriakopoulos, Christos P and Taleb, Iosif and Hurst, Denise and Ugolini, Sharon and Selzman, Craig H and Brinker, Lina and Drakos, Stavros G and Tonna, Joseph E and Geer, Laura and Goodwin, Matthew L and Wever-Pinzon, Omar and Hanff, Thomas C and Fang, James C and Carter, Spencer and Stehlik, Josef},
  title = {Bridge‐to‐transplant temporary mechanical circulatory support and risk of allosensitization},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15330}
}
Start for free →